# Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

> **NCT00445003** · PHASE3 · COMPLETED · sponsor: **Jaeb Center for Health Research** · enrollment: 333 (actual)

## Conditions studied

- Proliferative Diabetic Retinopathy
- Diabetic Macular Edema

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Triamcinolone Acetonide
- **BEHAVIORAL:** Sham injection
- **PROCEDURE:** Focal/grid laser

## Key facts

- **NCT ID:** NCT00445003
- **Lead sponsor:** Jaeb Center for Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-10
- **Final completion:** 2010-07
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2016-08-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445003, "Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00445003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*